^
Association details:
| Biomarker: | MSLN overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | gavocabtagene autoleucel (TC-210) (T-cell stimulant, Mesothelin inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
TCR² ANNOUNCES RECIST RESPONSE IN OVARIAN CANCER FROM ONGOING PHASE 1/2 TRIAL OF TC-210 IN TREATMENT REFRACTORY MESOTHELIN-EXPRESSING SOLID TUMORS
Published date:
12/13/2020
Excerpt:
TCR2 Therapeutics Inc. (Nasdaq: TCRR)...today announced positive interim data from the ongoing Phase 1 portion of the TC-210 ( gavocabtagene autoleucel or “gavo-cel”) Phase 1/2 clinical trial for mesothelin-expressing solid tumors...Ovarian cancer patient achieved confirmed RECIST partial response (PR)...Overall response rate (ORR) 50% in patients infused with TC-210...
